Bagley K C, Shata M T, Onyabe D Y, DeVico A L, Fouts T R, Lewis G K, Hone D M
Division of Vaccine Research and Basic Science, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W. Lombard Street, Baltimore, MD, 212001, USA.
Vaccine. 2003 Jul 4;21(23):3335-41. doi: 10.1016/s0264-410x(03)00038-0.
Passive antibody studies unequivocally demonstrate that sterilizing immunity against lentiviruses is obtainable through humoral mechanisms. In this regard, DNA vaccines represent an inexpensive alternative to subunit vaccine for mass vaccination programs designed to induce such responses to human immunodeficiency virus type I (HIV-1). At present, however, this vaccine modality has proven relatively ineffective at inducing humoral responses. In this report, we describe the immunogenicity of DNA vaccines that direct the coincident expression of the cholera toxin catalytic domain (CTA1) with that of the human immunodeficiency virus type I gp120 through genes either encoded in individual plasmids or in a single dicistronic plasmid. In BALB/cJ mice, coincident expression of CTA1 in either a separate plasmid or in the dicistronic plasmid in the DNA vaccines induced serum IgG responses to gp120 that were at least 1000-fold greater, and remained elevated longer than, the analogous responses in mice vaccinated with a DNA vaccine that expressed gp120 alone. In addition, mice vaccinated with CTA1 and gp120 produced significantly more gp120-specific IFN-gamma ELISPOTs than mice vaccinated with the gp120 DNA vaccine. Combined, these data show that the adjuvant properties of cholera toxin can be harnessed in DNA vaccine modalities.
被动抗体研究明确表明,通过体液机制可获得针对慢病毒的灭菌免疫。就此而言,对于旨在诱导针对I型人类免疫缺陷病毒(HIV-1)产生此类反应的大规模疫苗接种计划,DNA疫苗是亚单位疫苗的一种廉价替代方案。然而,目前已证明这种疫苗形式在诱导体液反应方面相对无效。在本报告中,我们描述了通过单个质粒或单个双顺反子质粒中编码的基因,指导霍乱毒素催化结构域(CTA1)与人免疫缺陷病毒I型gp120同时表达的DNA疫苗的免疫原性。在BALB/cJ小鼠中,DNA疫苗中单独质粒或双顺反子质粒中的CTA1同时表达诱导的针对gp120的血清IgG反应,比单独表达gp120的DNA疫苗接种的小鼠中的类似反应至少高1000倍,且持续升高的时间更长。此外,接种CTA1和gp120的小鼠产生的gp120特异性IFN-γ ELISPOT比接种gp120 DNA疫苗的小鼠显著更多。综合这些数据表明,霍乱毒素的佐剂特性可用于DNA疫苗形式。